Comprehensive Stock Comparison
Compare Syra Health Corp. Class A Common Stock (SYRA) vs Cryo-Cell International, Inc. (CCEL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SYRA | 44.7% revenue growth vs CCEL's 2.0% |
| Quality / Margins | CCEL | 1.3% net margin vs SYRA's -16.9% |
| Stability / Safety | CCEL | Beta 0.16 vs SYRA's 0.78 |
| Dividends | CCEL | 7.3% yield; SYRA pays no meaningful dividend |
| Momentum (1Y) | CCEL | -55.4% vs SYRA's -75.3% |
| Efficiency (ROA) | CCEL | 0.6% ROA vs SYRA's -38.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Syra Health is a healthcare services company that provides health education, population health management, behavioral health, workforce solutions, and digital health services. It generates revenue through service contracts with government agencies, health networks, and pharmaceutical manufacturers — primarily from its health education and population health management segments. The company's competitive advantage lies in its integrated service portfolio addressing multiple healthcare system pain points, including its Syrenity telehealth platform for mental health services.
Cryo-Cell International is a cellular processing and cryogenic storage company that preserves umbilical cord blood and tissue stem cells for family use. It generates revenue primarily from cord blood and cord tissue storage services—charging initial processing fees and annual storage fees—with additional income from selling its PrepaCyte CB processing technology to other storage facilities. The company's competitive advantage lies in its established reputation in the family cord blood banking market, proprietary processing technology, and direct-to-consumer marketing relationships with healthcare providers.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CCEL leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). SYRA leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
CCEL is the larger business by revenue, generating $32M annually — 4.2x SYRA's $7M. CCEL is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to SYRA's -16.9%. On growth, CCEL holds the edge at -3.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SYRASyra Health Corp.… | CCELCryo-Cell Interna… |
|---|---|---|
| RevenueTrailing 12 months | $7M | $32M |
| EBITDAEarnings before interest/tax | -$1M | $6M |
| Net IncomeAfter-tax profit | -$1M | $399,609 |
| Free Cash FlowCash after capex | -$231,031 | $6M |
| Gross MarginGross profit ÷ Revenue | +31.4% | +77.1% |
| Operating MarginEBIT ÷ Revenue | -16.9% | +13.6% |
| Net MarginNet income ÷ Revenue | -16.9% | +1.3% |
| FCF MarginFCF ÷ Revenue | -3.1% | +19.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -25.1% | -3.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +67.1% | -30.8% |
Valuation Metrics
| Metric | SYRASyra Health Corp.… | CCELCryo-Cell Interna… |
|---|---|---|
| Market CapShares × price | $60,000 | $27M |
| Enterprise ValueMkt cap + debt − cash | -$2M | $40M |
| Trailing P/EPrice ÷ TTM EPS | -0.19x | 67.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 9.97x |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 0.85x |
| Price / BookPrice ÷ Book value/share | 0.25x | — |
| Price / FCFMarket cap ÷ FCF | — | 7.53x |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), CCEL scores 7/9 vs SYRA's 3/9, reflecting strong financial health.
| Metric | SYRASyra Health Corp.… | CCELCryo-Cell Interna… |
|---|---|---|
| ROE (TTM)Return on equity | -57.3% | — |
| ROA (TTM)Return on assets | -38.8% | +0.6% |
| ROICReturn on invested capital | -2.9% | — |
| ROCEReturn on capital employed | -106.4% | +8.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 |
| Debt / EquityFinancial leverage | 0.16x | — |
| Net DebtTotal debt minus cash | -$2M | $12M |
| Cash & Equiv.Liquid assets | $2M | $560,960 |
| Total DebtShort + long-term debt | $452,077 | $13M |
| Interest CoverageEBIT ÷ Interest expense | -99.37x | 1.62x |
Total Returns (with DRIP)
A $10,000 investment in CCEL five years ago would be worth $5,120 today (with dividends reinvested), compared to $333 for SYRA. Over the past 12 months, CCEL leads with a -55.4% total return vs SYRA's -75.3%. The 3-year compound annual growth rate (CAGR) favors CCEL at 1.7% vs SYRA's -67.8% — a key indicator of consistent wealth creation.
| Metric | SYRASyra Health Corp.… | CCELCryo-Cell Interna… |
|---|---|---|
| YTD ReturnYear-to-date | +14.9% | -1.7% |
| 1-Year ReturnPast 12 months | -75.3% | -55.4% |
| 3-Year ReturnCumulative with dividends | -96.7% | +5.2% |
| 5-Year ReturnCumulative with dividends | -96.7% | -48.8% |
| 10-Year ReturnCumulative with dividends | -96.7% | +31.2% |
| CAGR (3Y)Annualised 3-year return | -67.8% | +1.7% |
Risk & Volatility
CCEL is the less volatile stock with a 0.16 beta — it tends to amplify market swings less than SYRA's 0.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CCEL currently trades 42.6% from its 52-week high vs SYRA's 24.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SYRASyra Health Corp.… | CCELCryo-Cell Interna… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 0.16x |
| 52-Week HighHighest price in past year | $0.41 | $7.91 |
| 52-Week LowLowest price in past year | $0.03 | $3.10 |
| % of 52W HighCurrent price vs 52-week peak | +24.4% | +42.6% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 49.7 |
| Avg Volume (50D)Average daily shares traded | 12K | 13K |
Analyst Outlook
CCEL is the only dividend payer here at 7.30% yield — a key consideration for income-focused portfolios.
| Metric | SYRASyra Health Corp.… | CCELCryo-Cell Interna… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | +7.3% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.25 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Sep 23 | Feb 26 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | 100 | 2.67 | -97.3% |
| Cryo-Cell Internati… (CCEL) | 100 | 63.89 | -36.1% |
Cryo-Cell Internati… (CCEL) returned -49% over 5 years vs Syra Health Corp. C… (SYRA)'s -97%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | $0.00 | $8M | — |
| Cryo-Cell Internati… (CCEL) | $21M | $32M | +51.7% |
Cryo-Cell International, Inc.'s revenue grew from $21M (2015) to $32M (2024) — a 4.7% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | -0.2% | -47.1% | -20147.6% |
| Cryo-Cell Internati… (CCEL) | 38.4% | 1.3% | -96.7% |
Cryo-Cell International, Inc.'s net margin went from 38% (2015) to 1% (2024).
Chart 4P/E Ratio History — 6 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| Cryo-Cell Internati… (CCEL) | 32.2 | 148.2 | +360.2% |
Cryo-Cell International, Inc. has traded in a 13x–148x P/E range over 6 years; current trailing P/E is ~67x.
Chart 5EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | -0 | -0.52 | -74185.7% |
| Cryo-Cell Internati… (CCEL) | 0.83 | 0.05 | -94.0% |
Cryo-Cell International, Inc.'s EPS grew from $0.83 (2015) to $0.05 (2024) — a -27% CAGR.
Chart 6Free Cash Flow — 5 Years
Syra Health Corp. Class A Common Stock generated $-3M FCF in 2024 (-3015% vs 2021). Cryo-Cell International, Inc. generated $4M FCF in 2024 (+270% vs 2021).
SYRA vs CCEL: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is SYRA or CCEL a better buy right now?
Cryo-Cell International, Inc. (CCEL) offers the better valuation at 67.4x trailing P/E, making it the more compelling value choice. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SYRA or CCEL?
Over the past 5 years, Cryo-Cell International, Inc. (CCEL) delivered a total return of -48.8%, compared to -96.7% for Syra Health Corp. Class A Common Stock (SYRA). A $10,000 investment in CCEL five years ago would be worth approximately $5K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CCEL returned +31.2% versus SYRA's -96.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SYRA or CCEL?
By beta (market sensitivity over 5 years), Cryo-Cell International, Inc. (CCEL) is the lower-risk stock at 0.16β versus Syra Health Corp. Class A Common Stock's 0.78β — meaning SYRA is approximately 374% more volatile than CCEL relative to the S&P 500.
04Which has better profit margins — SYRA or CCEL?
Cryo-Cell International, Inc. (CCEL) is the more profitable company, earning 1.3% net margin versus -47.1% for Syra Health Corp. Class A Common Stock — meaning it keeps 1.3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCEL leads at 10.9% versus -47.2% for SYRA. At the gross margin level — before operating expenses — CCEL leads at 75.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SYRA or CCEL?
In this comparison, CCEL (7.3% yield) pays a dividend. SYRA does not pay a meaningful dividend and should not be held primarily for income.
06Is SYRA or CCEL better for a retirement portfolio?
For long-horizon retirement investors, Cryo-Cell International, Inc. (CCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.16), 7.3% yield). Both have compounded well over 10 years (CCEL: +31.2%, SYRA: -96.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SYRA and CCEL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: SYRA is a small-cap quality compounder stock; CCEL is a small-cap income-oriented stock. CCEL pays a dividend while SYRA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.